Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Illinois governor Rod R. Blagojevich sent a letter on December 22 to Secretary of Health and Human Services Tommy Thompson asking that Thompson approve Illinois' plan to import pharmaceutical products from Canada for use by the state's employees and retirees. The governor, who has been pushing for months to gain the right to purchase drugs for Illinois from less-expensive sources in Canada, stated in his letter, “I was encouraged by your recent statements regarding your willingness to approve a small-scale demonstration project around the issue of re-importation of prescription drugs from Canada. We would like to work with you to design an effective pilot program that complies with the law.” Blagojevich hopes his state will become the “small-scale demonstration project” Thompson spoke of.
The Governor's Plan
Blagojevich cites the Medicare Prescription Drug Improvement and Modernization Act of 2003 as authorizing Thompson to approve Illinois' program. According to Blagojevich, Thompson could certify to Congress under ' 804(1) of the Act that for the narrow purposes of Illinois' pilot program, re-importation would pose no additional risk to the public's health and safety, and would result in a significant reduction in the cost of prescription drugs to consumers. Then, according to the governor, Thompson could use the authority granted to him under the Act to grant waivers of the prohibition against re-importation of an agreed list of prescription drugs.
To ensure safety, the Illinois plan would, among other things, limit its list of drugs for re-importation primarily to brand-name drugs, and to those approved by the FDA that come in FDA-approved dosages. Blagojevich's plan would also call for the University of Illinois College of Pharmacy to monitor the program to evaluate the safety and efficacy of the drugs received by plan participants.
Likely Outcome
But representatives of HHS have indicated that such a program is not likely to be approved unless Thompson can be assured of the safety of the imported drugs. The New York Times reported on December 23 that HHS's associate commissioner for external relations, Peter Pitts, says that safety is the agency's central concern, and drug products imported from Canada pose risks such as false labeling and counterfeiting.
Blagojevich's letter asks Thompson to give his answer within 30 days. The letter is posted at http://www.illinois.gov/PressReleases/.
Illinois governor Rod R. Blagojevich sent a letter on December 22 to Secretary of Health and Human Services Tommy Thompson asking that Thompson approve Illinois' plan to import pharmaceutical products from Canada for use by the state's employees and retirees. The governor, who has been pushing for months to gain the right to purchase drugs for Illinois from less-expensive sources in Canada, stated in his letter, “I was encouraged by your recent statements regarding your willingness to approve a small-scale demonstration project around the issue of re-importation of prescription drugs from Canada. We would like to work with you to design an effective pilot program that complies with the law.” Blagojevich hopes his state will become the “small-scale demonstration project” Thompson spoke of.
The Governor's Plan
Blagojevich cites the Medicare Prescription Drug Improvement and Modernization Act of 2003 as authorizing Thompson to approve Illinois' program. According to Blagojevich, Thompson could certify to Congress under ' 804(1) of the Act that for the narrow purposes of Illinois' pilot program, re-importation would pose no additional risk to the public's health and safety, and would result in a significant reduction in the cost of prescription drugs to consumers. Then, according to the governor, Thompson could use the authority granted to him under the Act to grant waivers of the prohibition against re-importation of an agreed list of prescription drugs.
To ensure safety, the Illinois plan would, among other things, limit its list of drugs for re-importation primarily to brand-name drugs, and to those approved by the FDA that come in FDA-approved dosages. Blagojevich's plan would also call for the University of Illinois College of Pharmacy to monitor the program to evaluate the safety and efficacy of the drugs received by plan participants.
Likely Outcome
But representatives of HHS have indicated that such a program is not likely to be approved unless Thompson can be assured of the safety of the imported drugs. The
Blagojevich's letter asks Thompson to give his answer within 30 days. The letter is posted at http://www.illinois.gov/PressReleases/.
Our friends at Edge Marketing are ending the year by sharing their predictions for 2025. From the continued evolution of generative AI and its many uses to an increase in multimedia and hypertargeting, these are some of the key factors that will guide legal marketing strategies in the new year.
As organizations enhance their e-discovery processes and infrastructure, the expectation to leverage technology to maximize service delivery increases. However, legal professionals must balance innovation with humanity.
The business-law issue of whether and when a corporate defendant is considered distinct from its affiliated entities emerged on December 11 at the U.S. Supreme Court, with the justices confronting whether a non-defendant’s affiliate’s revenue can be part of a judge’s calculation of the monetary remedy for the corporate defendant’s infringement of a trademark.
The most forward-thinking companies embrace AI with complete confidence because they have created governance programs that serve as guardrails for this incredible new technology. Effective governance ensures AI consistently aligns with an organization’s best interests, safeguarding against potential risks while unlocking its full potential.
It’s time for our annual poll of experts on what they expect 2025 to bring in legal tech, including generative AI (of course), e-discovery, and more.